Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “antagonist”

678 pharma patents match "antagonist" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 678
Index total 30,257
Page 8 / 29

Quick answer

This filtered view shows 678 pharmaceutical patents matching "antagonist" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

678 results for “antagonist” · 30,257 patents in full index Clear search

  1. US 10626146

    α4β7 thioether peptide dimer antagonists

    Protagonist Therapeutics, Inc. · Granted Apr 21, 2020 · Expires Apr 16, 2040

    granted
  2. CA 3112060

    COMPOSITION PHARMACEUTIQUE COMPRENANT UN ANTAGONISTE DE GPRP RADIOMARQUE ET UN TENSIOACTIF

    ADVANCED ACCELERATOR APPLICATIONS INT SA [CH] · Granted Apr 16, 2020 · Expires Apr 11, 2040

    granted
  3. US 10617673

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Apr 14, 2020 · Expires Apr 9, 2040

    granted
  4. US 10610534

    Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency

    Corcept Therapeutics Incorporated · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  5. US 10604507

    Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

    CRINETICS PHARMACEUTICALS, INC. · Granted Mar 31, 2020 · Expires Mar 26, 2040

    granted
  6. US 10597448

    Methods for treating visceral pain associated with interstitial cystitis by administering antagonist antibodies directed against calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Mar 24, 2020 · Expires Mar 19, 2040

    granted
  7. US 10590107

    Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity

    Theravance Respiratory Company, LLC · Granted Mar 17, 2020 · Expires Mar 12, 2040

    granted
  8. US 10577361

    Dopamine D3 receptor antagonists having a morpholine moiety

    Indivior UK Limited · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  9. US 10570092

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Feb 25, 2020 · Expires Feb 20, 2040

    granted
  10. US 10562884

    Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

    CRINETICS PHARMACEUTICALS, INC. · Granted Feb 18, 2020 · Expires Feb 13, 2040

    granted
  11. US 10556945

    Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 11, 2020 · Expires Feb 6, 2040

    granted
  12. US 10544188

    Inhibitor of apoptosis protein (IAP) antagonists

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Jan 28, 2020 · Expires Jan 23, 2040

    granted
  13. US 10538530

    Vasopressin receptor antagonists and products and methods related thereto

    BLACKTHORN THERAPEUTICS, INC. · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted
  14. US 10532096

    Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 14, 2020 · Expires Jan 9, 2040

    granted
  15. CA 3105778

    POLYTHERAPIE AVEC DES ANTAGONISTES DU CGRP ET DES DERIVES DE CLOSTRIDIUM

    ALLERGAN PHARMACEUTICALS INT LTD [IE] · Granted Jan 9, 2020 · Expires Jan 4, 2040

    granted
  16. US 10508103

    Benzimidazole-linked indole compound acting as novel divalent IAP antagonist

    Medshine Discovery Inc. · Granted Dec 17, 2019 · Expires Dec 12, 2039

    granted
  17. US 10464992

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  18. US 10456380

    Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonists

    Cumberland Pharmaceuticals Inc. · Granted Oct 29, 2019 · Expires Oct 24, 2039

    granted
  19. US 10407468

    Methods for synthesizing α4β7 peptide antagonists

    Protagonist Therapeutics, Inc. · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted
  20. US 10407443

    5-HT3 receptor antagonists

    Takeda Pharmaceutical Company Limited · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted
  21. US 10406226

    Method of manufacturing VEGF antagonist fusion proteins

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted
  22. US 10400025

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 3, 2019 · Expires Aug 29, 2039

    granted
  23. US 10377751

    8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Aug 13, 2019 · Expires Aug 8, 2039

    granted
  24. US 10369142

    Combination dosage form of a mu opioid receptor antagonist and an opioid agent

    Theravance Biopharma R&D IP, LLC · Granted Aug 6, 2019 · Expires Aug 1, 2039

    granted